Matterworks

Matterworks operates at the intersection of AI and metabolomics, the study of small molecules within a cell. The company targets the unsustainable costs and time associated with life science research and development. Its business model centers on providing a "model as a service" (MaaS) to clients in sectors such as therapeutic research, biomanufacturing, crop science, and animal health. This approach is designed to make the powerful analytical technique of mass spectrometry more accessible to a broader range of biologists.

The company's core technology is its AI platform, which features a proprietary Large Spectral Model (LSM), analogous to a large language model, for interpreting unstructured molecular-omic data. In 2024, Matterworks launched Pyxis™, a generative AI product that provides a turn-key solution for identifying and quantifying metabolites from raw mass spectrometry data. Pyxis transforms this uninterpreted data into biologically actionable insights, significantly reducing analysis time from weeks to near real-time. This enables researchers to better understand and predict complex biological outcomes, impacting everything from therapeutic protein production to the development of sustainable agricultural inputs.

The company has successfully raised $15.9 million over four funding rounds, culminating in a Series A in June 2025. This latest round was led by Lewis & Clark Partners and OMX Ventures, with participation from other investors including Pillar VC and Germin8 Ventures, to fund the expansion of its MaaS business and operational growth.